



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.  
Phone : +91 92280 16100 - 03 | +91 79 2646 8353, 4002 3839 | Fax : +91 79 2640496 |  
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.  
E-mail : [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | [ishitadrugs@vsnl.net](mailto:ishitadrugs@vsnl.net) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)



Date: 29<sup>th</sup> May, 2018

To,  
The Company Section  
The Bombay Stock Exchange  
Phiroz Jijibhoy Towers  
Dalal Street, Bombay- 400 001

**Security Code: 524400**

Dear Sir,

**Sub: Outcome of Board Meeting held on 29th May, 2018 pursuant to Regulation 30 of SEBI(LODR) Regulation, 2015.**

This is to inform you that the Board of directors of the Company at its meeting held today on Tuesday, 29<sup>th</sup> May, 2018 has Approve the Audited Financial Results of the Company of the quarter and year ended on 31<sup>st</sup> March, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby enclose the following:-

1. Approved the Audited Financial Results of the Quarter and Year ended 31<sup>st</sup> March, 2018
2. Auditors Reports on Audited Financial Results
3. Declaration regarding unmodified audit report along with Form "A"

The aforesaid is for kind information and doing the needful in the matter

Hope the enclosed papers are in accordance with requirements.

Please acknowledge receipt

Thanking You.

For, Ishita Drugs & Industries Ltd.

\_\_\_\_\_  
Authorized Signatory



*"Our basic drugs in the service of humanity worldwide"*

**CIN No. L24231GJ1992PLC017054**  
D & B D-U-N-S Number: - 65-018-0359

**ISHITA DRUGS AND INDUSTRIES LIMITED**

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand  
Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: 7226995613/14/15

**Audited Financial Results for the Quarter and Year Ended March 31, 2018**

Amount in Lacs except Per Share data

Particulars	3 Months Ended	Preceding 3 Months Ended	corresponding 3 Months Ended in the previous year	Year to date figures for current year ended	Year to Date Figure for the previous year ended
	Audited	Un-audited	Audited	Audited	Audited
	31-Mar-18	31-Dec-17	31-Mar-17	31-Mar-18	31-Mar-17
<b>1 INCOME</b>					
Revenue from Operations	239.81	114.41	217.83	689.98	640.04
Other Income	5.81	3.96	5.96	11.93	12.02
<b>Total Income</b>	<b>245.62</b>	<b>118.37</b>	<b>223.79</b>	<b>701.91</b>	<b>652.06</b>
<b>2 EXPENSES</b>					
(a) Cost of Material Consumed	191.54	90.23	124.55	476.74	369.02
(b) Purchase of Stock-In-Trade	(3.70)	3.64	5.40	9.23	15.47
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(1.15)	(25.51)	15.05	(12.71)	12.74
(d) Employee Benefit Expense	20.06	20.06	19.20	79.99	69.17
(e) Finance Cost	8.95	0.82	3.08	11.26	4.46
(f) Depreciation, Depletion and Amortisation Expense	3.11	3.50	1.44	13.61	13.99
(g) Total Other Expenses	14.35	18.80	45.38	90.76	141.51
<b>Total Expenses</b>	<b>233.16</b>	<b>111.54</b>	<b>214.10</b>	<b>668.88</b>	<b>626.36</b>
<b>3 Total Profit before Exceptional Items and Tax</b>	<b>12.46</b>	<b>6.83</b>	<b>9.69</b>	<b>33.03</b>	<b>25.70</b>
<b>4 Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>5 Total Profit before Tax</b>	<b>12.46</b>	<b>6.83</b>	<b>9.69</b>	<b>33.03</b>	<b>25.70</b>
<b>6 Tax Expense</b>					
7 Current Tax	4.21	0.90	4.50	8.71	8.50
8 Deferred Tax	(0.46)	0.00	(1.05)	(0.46)	(1.05)
<b>9 Total Tax Expenses</b>	<b>3.75</b>	<b>0.90</b>	<b>3.45</b>	<b>8.25</b>	<b>7.45</b>
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00
<b>11 Net Profit Loss for the period from continuing operations</b>	<b>8.71</b>	<b>5.93</b>	<b>6.24</b>	<b>24.78</b>	<b>18.25</b>
12 Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00
13 Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00
<b>14 Net Profit / (Loss) from discontinued operations after tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00
<b>16 Total Profit / (Loss) for the period</b>	<b>8.71</b>	<b>5.93</b>	<b>6.24</b>	<b>24.78</b>	<b>18.25</b>
17 Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00
<b>18 Total Comprehensive Income for the Period</b>	<b>8.71</b>	<b>5.93</b>	<b>6.24</b>	<b>24.78</b>	<b>18.25</b>

*for details see attached*



Amount in Lacs except Per Share data

Particulars					
	3 Months Ended	Preceding 3 Months ended	Corresponding 3 Months Ended in previous year	Year to date figures for current year	Year to date figures for the Previous year Ended
	Audited	Un-audited	Audited	Audited	Audited
	31-Mar-18	31-Dec-17	31-Mar-17	31-Mar-18	31-Mar-17
<b>19 Total profit or loss attributable to</b>					
Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00
Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00
<b>20 Total comprehensive income for the period attributable to</b>					
Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00
Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00
<b>21 Details of Equity Share Capital</b>					
Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03
Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
<b>22 Details of Debt Securities</b>					
Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00
Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00
23 Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00
24 Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00
<b>25 Earnings Per Share</b>					
<b>(i) Earnings Per Share for continuing operations</b>					
Basic Earnings / (Loss) per share from continuing operations	0.29	0.20	0.21	0.83	0.61
Diluted Earnings / (Loss) per share from continuing operations	0.29	0.20	0.21	0.83	0.61
<b>(ii) Earnings Per Share for discontinued operations</b>					
Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
<b>(iii) Earnings per Equity Share</b>					
Basic Earnings / (Loss) per share from continuing and discontinued operations	0.29	0.20	0.21	0.83	0.61
Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.29	0.20	0.21	0.83	0.61
26 Debt Equity Ratio*	0.00	0.00	0.00	0.00	0.00
27 Debt Service Coverage Ratio*	0.00	0.00	0.00	0.00	0.00
28 Interest Service Coverage Ratio*	0.00	0.00	0.00	0.00	0.00

The Company adopted Indian Accounting Standards (IndAS) from April 1, 2017 as per road map released by Ministry of Corporate Affairs (MCA). Reconciliation of Net Profit after tax as previously reported under Indian GAAP and IndAS for the quarter and year ended march 31, 2018, is as follows:

Description	Year Ended	Year Ended
	31-Mar-18	31-Mar-17
Net Profit as per Previous Indian GAAP	24.78	18.25
Net Profit as per IndAS	24.78	18.25



Jeyaraj Arum

**ISHITA DRUGS AND INDUSTRIES LIMITED**

**CIN: L24231GJ1992PLC017054**

**Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand  
Ahmedabad – 382170**

**Website: www.ishitadrugs.com**

**Contact: 7226995613/14/15**

**NOTES**

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on May 29, 2018
2. The above financial results have been prepared In accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Amendment Rules, 2016
3. The Audit as required under Regulation 33 of the SEBI (LODR), Regulation 2015 has been completed by the Auditor of the company. There are no qualifications in the Auditors Report For the Year Ended March 31, 2018.
4. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
5. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
6. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
7. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED		
		<b>JAGDISH AGRAWAL</b>
Place Ahmedabad		<b>MANAGING DIRECTOR</b>
Date 31-Mar-18		<b>DIN: 01031687</b>

*Jagdish Agrawal*



**ISHITA DRUGS AND INDUSTRIES LIMITED**

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 9228016100

**Statement of Assets and Liabilities**

Particulars	Year Ended	Previous Year Ended
	12 Months Ended	12 Months Ended
	Audited	Audited
	31-Mar-18	31-Mar-17
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
Property, plant and equipment	11879886	10171144
Capital work-in-progress		
Investment property		
Goodwill		
Other intangible assets		
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
<b>Non-current financial assets</b>	11879886	10171144
Non-current investments	1592254	1592254
Trade receivables, non-current		
Loans, non-current	498200	498200
Other non-current financial assets		
<b>Total Non-current financial assets</b>	2090454	2090454
Deferred tax assets (net)		
Other non-current assets		
<b>Total Non-current Assets</b>	13970340	12261598
<b>2 Current assets</b>		
Inventories	7200886	5616304
<b>Current financial assets</b>		
Current investments	29936585	25361292
Trade receivables, current	8215528	17040975
Cash and cash equivalents	251974	1174114
Bank balance other than cash and cash equivalents	6500088	3051072
Loans, current	736491	89175
Other current financial assets	5377578	7050239
<b>Total current financial assets</b>	51018244	53766867
Current tax assets (net)		
Other current assets		
<b>Total Current Assets</b>		
<b>3 Non-current assets classified as held for sale</b>		
<b>4 Regulatory deferral account debit balances and related deferred tax Assets</b>		
<b>TOTAL ASSETS</b>	<b>72189470</b>	<b>71644769</b>

*Jaydeep Agrawal*



EQUITIES AND LIABILITIES			
1	<b>Equity</b>		
	<b>Equity attributable to owners of Parent</b>		
	Equity share capital	29903000	29903000
	Other equity	30720893	28242900
	<b>Total Equity attributable to owners of Parent</b>	60623893	58145900
	Non controlling interest		
	<b>Total Equity</b>	<b>60623893</b>	<b>58145900</b>
2	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	<b>Non-current financial liabilities</b>		
	Borrowing, non-current	849413	
	Trade payables, non-current		
	Other non-current financial liabilities		
	<b>Total Non-current financial liabilities</b>	849413	
	Provisions, non-current		
	Deferred tax liabilities (net)	593317	639428
	Deferred government grants, Non-current Other non-current liabilities		
	<b>Total Non-current liabilities</b>	<b>593317</b>	<b>639428</b>
	<b>Current liabilities</b>		
	<b>Current financial liabilities</b>		
	Borrowing, current	417537	72229
	Trade payables, current	5616188	11816720
	Other current financial liabilities		
	<b>Total current financial liabilities</b>	6033725.00	11888949.00
	Other current liabilities	2932592	61652
	Provisions, current	1156530	908840
	Current tax liabilities (Net)		
	Deferred government grants, Current		
	<b>Total current liabilities</b>	<b>4089122</b>	<b>970492</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	<b>Total Liabilities</b>		
	<b>Total Equity and Liabilities</b>	<b>72189470</b>	<b>71644769</b>

For, ISHITA DRUGS AND INDUSTRIES LIMITED

		<b>JAGDISH AGRAWAL</b>
Place	Ahmedabad	<b>MANAGING DIRECTOR</b>
Date	29-May-18	<b>DIN: 01031687</b>

*Jagdish Agrawal*



# PRATIK KAUSHIKKUMAR KIKANI

MRN – 180309

CHARTERED ACCOUNTANTS

PAN –ATVPK1876E

**Auditor's Report on Annual Financial Results of M/s Ishita Drugs & Industries Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors  
Ishita Drugs & Industries Ltd

We have audited the statement of Annual financial results of M/s Ishita Drugs & Industries Ltd for the year ended 31<sup>st</sup> March, 2018, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These statement is the responsibility of the company's management and has been approved by the Board of Directors. This statement has been prepared on the basis of the annual financial statements. Our responsibility is to express an opinion on these financial results based on our audit of such annual financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the period from 01<sup>st</sup> April, 2017 to 31<sup>st</sup> March, 2018.

The financial results include the results for the Quarter ended March 31, 2018, being the balancing figure between audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year, which were subject to limited review by us.

Date: 29/05/2018  
Place: Ahmedabad



For and on behalf of  
PRATIK KAUSHIKKUMAR KIKANI  
Chartered Accountants

*Kikani Pratik*

CA Pratik Kaushikkumar Kikani  
M.NO.180309

B-87/1, Rajbaug Society, Canal Road, Ghodasar, Ahmedabad – 380050

Telephone - 9687674839 / 9662263926 Mail - kikanipratik@yahoo.co.in



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.  
Phone : +91 92280 16100 - 03 | +91 79 2646 8353, 4002 3839 | Fax : +91 79 26404961  
Regd. Office & Factory : 179/1, Vasna-lyava, Tal. Sanand, Dist. : Ahmedabad.  
E-mail : [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | [ishitadrugs@vsnl.net](mailto:ishitadrugs@vsnl.net) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)



Date: 29<sup>th</sup> May, 2018

To,  
The Company Section  
The Bombay Stock Exchange  
Phiroz Jijibhoy Towers  
Dalal Street, Bombay- 400 001

**Security Code: 524400**

Dear Sir,

**Ref: Ishita Drugs and industries limited**

**Sub: Declaration regarding unmodified Audit Report in respect of standalone financial statement for the year 2017-18, under SEBI (LODR) Regulation, 2015.**

We hereby declare that we are hereby submitting the Audit Report in respect of standalone financial statement for the financial year 2017-18 along with the financial results on 29<sup>th</sup> May, 2018. Pursuant to the requirement 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 we hereby declare that the auditors have expressed an unmodified opinion in their audit reports on standalone financial statement of the company for the financial year 2017-18.

Thanking You.

For, Ishita Drugs & Industries Ltd.

\_\_\_\_\_  
Authorized Signatory



*"Our basic drugs in the service of humanity worldwide"*

**CIN No. L24231GJ1992PLC017054**  
D & B D-U-N-S Number: - 65-018-0359